Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis

European Urology

Volumn 69, Issue 1, 2016, Pages 107-115

  Sommariva, Silvia ^a   Tarricone, Rosanna ^a   Lazzeri, Massimo ^b   Ricciardi, Walter ^c   Montorsi, Francesco ^b  

^a BOCCONI UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Cell cycle progression score; Prognostic value; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; MESSENGER RNA;

BIOCHEMICAL RECURRENCE; CANCER PROGNOSIS; CELL CYCLE PROGRESSION SCORE; EMBASE; GLEASON SCORE; HUMAN; INFORMATION RETRIEVAL; MALE; MEDLINE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSTATE CANCER; PUBLICATION; QUALITY CONTROL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; CELL CYCLE; GENE; GENETICS; META ANALYSIS; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

CELL CYCLE; GENES, CDC; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84955690775     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.11.038     Document Type: Review

References (49)

1. US Cancer Statistics Working Group. United States cancer statistics: 1999-2010 incidence and mortality web-based report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013.
2. Health at a glance 2011: OECD data. Mortality from cancer. http://www.oecd-ilibrary.org/sites/health-glance-2011-en/01/04/index.html?itemId=/content/chapter/health-glance-2011-7-en
3. Istituto Toscano Tumori. Carcinoma della prostata: raccomandazioni cliniche. http://www.ittumori.it/ITA/pubblicazioni/raccomandazioni-cliniche-2012/05-prostata.pdf
4. G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, and et al. Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
5. C.R. Chen Making individualized decisions in the midst of uncertainties: the case of prostate cancer and biochemical recurrence Eur Urol 64 2013 916 918
6. D.M. Latini, S.L. Hart, S.J. Knight, and et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance J Urol 178 2007 826 831
7. T.J. Wilt, M.K. Brawer, M.K. Jones, and et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
8. O. Dillioglugil, B.D. Leibman, N.S. Leibman, M.W. Kattan, A.L. Rosas, and P.T. Scardino Risk factors for complications and morbidity after radical retropubic prostatectomy J Urol 157 1997 1760 1767
9. H. Heinzer, M. Graefen, J. Noldus, P. Hammerer, and H. Huland Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience Urol Int 59 1997 30 33
10. P.J. Davidson, D. van den Ouden, and F.H. Schroeder Radical prostatectomy: prospective assessment of mortality and morbidity Eur Urol 29 1996 168 173
11. W.J. Catalona, G.F. Carvalhal, D.E. Mager, and D.S. Smith Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies J Urol 162 1999 433 438
12. G.J. Huang, N. Sadetsky, and D.F. Penson Health related quality of life for men treated for localized prostate cancer with long-term followup J Urol 183 2010 2206 2212
13. P.D. Smith, M.T. King, S. Egger, and et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study BMJ 339 2009 b4817
14. M.J. van de Vijver, Y.D. He, L.J. van't Veer, and et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
15. Y. Wang, J.G. Klijn, Y. Zhang, and et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 2005 671 679
16. H.Y. Chang, D.S. Nuyten, J.B. Sneddon, and et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci U S A 102 2005 3738 3743
17. C. Sotiriou, and C. Desmedt Gene expression profiling in breast cancer Ann Oncol 17 Suppl 10 2006 259 262
18. M. Loddo, S.R. Kingsbury, M. Rashid, and et al. Cell-cycle phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer Br J Cancer 100 2009 959 970
19. A. Kern, and A.W. Partin Genetic tests for prostate cancer Rev Urol 15 2013 208 209
20. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
21. N.L. Wilczynski, and B. Haynes Optimal search strategies for detecting clinically sound prognostic studies in EMBASE: an analytic survey J Am Med Inform Assoc 12 2005 481 485
22. P.A. Hall, and J.J. Going Predicting the future: a critical appraisal of cancer prognosis studies Histopathology 35 1999 489 494
23. D.G. Altman, and R.D. Riley Primer: an evidence-based approach to prognostic markers Nat Clin Pract Oncol 2 2005 466 472
24. M.L. Sousa, and A.L. Ribeiro Systematic review and meta-analysis of diagnostic and prognostic studies Arq Bras Cardiol 92 2009 229 238
25. T.S. Rector, B.C. Taylor, and T.J. Wilt Systematic review of prognostic tests. Methods guide - Chapter 12. Department of Health and Human Services Agency for Healthcare Research and Quality; 2012
26. M. Drummond, M. Schulpher, G. Torrance, and et al. Methods for the economic evaluation of health care programmes 2005 Oxford University Press Oxford
27. M.R. Cooperberg, J.P. Simko, J.E. Cowan, and et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort J Clin Oncol 31 2013 1428 1434
28. J. Cuzick, G.P. Swanson, J. Fisher, and et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study Lancet Oncol 12 2011 245 255
29. N. Shore, R. Concepcion, D. Saltzstein, and et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer Curr Med Res Opin 30 2013 547 553
30. J. Cuzick, D.M. Berney, G. Fisher, and et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer 106 2012 1095 1099 2012
31. S.J. Freedland, L. Gerber, J. Reid, and et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy Int J Radiat Oncol Biol Phys 86 2013 848 853
32. J.T. Bishoff, S.J. Freedland, L. Gerber, and et al. Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy J Urol 192 2014 409 414
33. E.D. Crawford, M.C. Scholz, A.J. Kar, and et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry J Clin Oncol 30 2014 1025 1031
34. Centers for Disease Control and Prevention. ACCE model process for evaluating genetic tests. January 3, 2010. http://www.cdc.gov/genomics/gtesting/ACCE/
35. D.E. Crawford, N. Shore, P.T. Scardino, and et al. CCP score and risk stratification for prostate cancer patients at biopsy J Clin Oncol 32 Suppl 4 2014 47
36. N.D. Shore, B. Abbott, R.S. Concepcion, and et al. Stratification of risk for patients with prostate cancer at biopsy using CCP score J Clin Oncol 31 Suppl 6 2013 127
37. T. Schlomm, Z. Sangale, J.S. Lanchbury, and et al. Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology J Clin Oncol 31 Suppl 15 2013 5043
38. M.K. Brawer, J.M. Cuzick, M.R. Cooperberg, and et al. Prolaris: a novel genetic test for prostate cancer prognosis J Clin Oncol 31 Suppl 15 2013 5005
39. J.M. Cuzick, S. Stone, G. Fisher, and et al. Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort J Urol 191 4 Suppl 2014 e936
40. M.R. Cooperberg, S.J. Freedland, T. Schlomm, and et al. Predicting radical prostatectomy outcome: cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7 J Clin Oncol 32 Suppl 4 2014 13
41. F. Carvalho, W. Welbourn, J. Reid, and et al. Evidence for a cell cycle proliferation "field effect" in prostate cancer J Urol 189 Suppl 4 2013 e605
42. M.K. Brawer, M.L. Cooperberg, S. Freedland, and et al. Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort J Clin Oncol 31 Suppl 6 2013 67
43. J.K. Salama, S. Freedland, L. Gerber, and et al. Cell cycle progression (CCP) score significantly predicts PSA failure after EBRT Int J Radiat Oncol Biol Phys 87 2013 125
44. R. Luengo-Fernandez, J. Leal, A. Gray, and R. Sullivan Economic burden of cancer across the European Union: a population based cost analysis Lancet Oncol 14 2013 1165 1174
45. C.G. Roehrborn, and L.K. Black The economic burden of prostate cancer BJU Intl 108 2011 806 813
46. H. Miyake, and M. Fujisawa Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches Int J Urol 20 2013 301 311
47. U. Capitanio, A. Briganti, A. Gallina, and et al. Predictive models before and after radical prostatectomy Prostate 70 2010 1371 1378
48. Associazione Italiana di Oncologia Medica. Linee guida carcinoma della prostata AIOM 2013. http://www.aiom.it
49. R. Riley, P.C. Lambert, and G. Abo-Zaid Meta-analysis of individual participant data: rationale, conduct, and reporting BMJ 340 2010 c221